Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

Growth, Puberty, and Inborn Errors of Metabolism

Paediatric endocrinologists and general paediatricians frequently evaluate children for deviations in normal growth trajectories and pubertal timing. Concurrently, the acute presentation of an inborn error of metabolism (IEM) in a neonate or infant represents one of the most intellectually demanding and time-sensitive emergencies in medicine. Mastery of growth kinetics, bone age interpretation, hypothalamic-pituitary-gonadal (HPG) axis dynamics, and the "metabolic quartet" laboratory approach is essential for passing the European Board of Paediatrics (EBP-EAP) examination.

---

Growth Assessment and Short Stature Workup

Clinical Anthropometry and Growth Kinetics

• Measurement Technique: Measure supine length from birth up to 2 years using a calibrated stadiometer board with a fixed headboard and movable footboard (two examiners required). Measure standing height using a wall-mounted stadiometer from 2 years of age onwards.
• Normal Growth Velocity by Developmental Stage:
  • Infancy (0 to 12 months): 25 cm/year
  • Second year (12 to 24 months): 10 to 12 cm/year
  • Childhood (3 years to onset of puberty): 5 to 7 cm/year
  • Pubertal growth spurt: 8 to 12 cm/year (peaking at Tanner stage B3 in girls and G4 in boys)

Mid-Parental Target Height Calculation

The Tanner Mid-Parental Target Height estimates the child's genetic growth potential based on biological parental heights:

$\text{Target Height for Boys (cm)} = \frac{\text{Father's Height} + \text{Mother's Height} + 13\text{ cm}}{2}$ $\text{Target Height for Girls (cm)} = \frac{\text{Father's Height} - 13\text{ cm} + \text{Mother's Height}}{2}$

• The target height range is defined as the target height $\pm 8.5\text{ cm}$ (representing the 3rd to 97th percentile range for that family).

Bone Age Radiography

• Evaluated using a single anterior-posterior radiograph of the left hand and wrist, compared against the standardized Greulich and Pyle atlas or calculated via the Tanner-Whitehouse (TW3) method.
• Bone age reflects biological and skeletal maturity. Delayed bone age signifies remaining growth potential, whereas advanced bone age indicates premature epiphyseal fusion and compromised final adult height.

Differential Diagnosis of Short Stature (Height < -2 SDS or < 3rd Percentile)

Pathological Causes of Short Stature

1. Proportionate Short Stature:
   • Systemic Chronic Disease: Coeliac disease (mandatory screening with anti-tissue transglutaminase IgA / anti-tTG), Inflammatory Bowel Disease (Crohn's disease may present solely as growth arrest before gastrointestinal symptoms), Chronic Kidney Disease, congenital heart disease, cystic fibrosis.
   • Endocrine Disorders:
     • Growth Hormone Deficiency (GHD): Low serum IGF-1 and IGFBP-3; failure to increase GH levels ($>7\text{--}10\text{ mcg/L}$) on two separate pharmacological provocation tests (clonidine, arginine, or glucagon). Pituitary MRI indicated.
     • Hypothyroidism: Growth arrest with preserved or increasing weight curve.
     • Cushing Syndrome: Growth failure accompanied by rapid central weight gain, moon facies, and purple striae.
2. Disproportionate Short Stature (Altered Upper-to-Lower Segment Ratio):
   • Skeletal Dysplasias: Achondroplasia (autosomal dominant gain-of-function mutation in FGFR3; rhizomelic limb shortening, macrocephaly, frontal bossing, trident hands, normal trunk length).
3. Genetic and Syndromic Causes:
   • Turner Syndrome (45,X): Mandatory karyotyping in ANY girl with unexplained short stature or pubertal delay, regardless of whether classic somatic stigmata (webbed neck, low posterior hairline, cubitus valgus, broad "shield" chest, coarctation of aorta, bicuspid aortic valve) are evident. Missing or altered sex-chromosome material causes Turner syndrome; SHOX haploinsufficiency contributes to its short stature and skeletal features.
   • Noonan Syndrome: Autosomal dominant (PTPN11 mutations); short stature, webbed neck, pectus excavatum, pulmonary valve stenosis.
   • Prader-Willi Syndrome: Paternal deletion on 15q11-q13; infantile hypotonia, childhood hyperphagia, morbid obesity, hypogonadism.

---

Follow-up After Fetal Growth Restriction

Fetal growth restriction means failure to achieve growth potential; it is not identical to being statistically small for gestational age (SGA). Beyond neonatal complications, affected children need follow-up for growth and neurodevelopment. Persistent short stature and developmental difficulties may require specialist assessment. SGA birth is also associated with later cardiometabolic risk, particularly with excessive postnatal weight gain. Support adequate nutrition and proportional catch-up growth without promoting excess weight gain; monitor length/height, weight and development, and counsel about healthy activity and diet. Refer persistent short stature or developmental concerns for evaluation rather than assuming all small newborns will catch up normally.

Sources: RCOG growth-restriction guidance; international SGA consensus.

---

Disorders of Puberty: Precocious and Delayed

Puberty is initiated by the reactivation of the Hypothalamic-Pituitary-Gonadal (HPG) axis, resulting in pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH) by the hypothalamus, stimulating pituitary secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which drive gonadal sex steroid production.

Normal Pubertal Milestones (Tanner Staging)

• Girls: The first physical sign of female puberty is thelarche (breast budding, Tanner stage B2), occurring between 8 and 13 years of age. Menarche is a late milestone, occurring approximately 2 to 2.5 years after thelarche (average age: 12.5 years, Tanner stage B3–B4).
• Boys: The first physical sign of male puberty is testicular enlargement (volume $\ge 4\text{ mL}$) measured using a Prader orchidometer (Tanner stage G2), occurring between 9 and 14 years of age.

                 [Early or rapidly progressive pubertal development]
                   (<8y girls, <9y boys: assess growth and Tanner stage)
          [Girls with isolated stable B2: reassess in 4–6 months;
           investigate B3/progression/growth acceleration or CNS signs]
                                        |
                      [Ultrasensitive basal serum LH first]
                                        |
             +--------------------------+--------------------------+
             |                                                     |
[Pubertal LH: supports central puberty]            [Low LH despite convincing clinical signs]
             |                                     [GnRH/GnRHa stimulation if needed]
             |                                                     |
             +------------------ [Interpret with clinical course] --+
                                        |
             +--------------------------+--------------------------+
             |                                                     |
[Central: HPG-axis activation]                  [Peripheral: gonadal/adrenal sex steroids]
[MRI for younger children or CNS signs]         [Pelvic/testicular/adrenal imaging as indicated]
[No routine MRI without CNS signs in            [Ovarian cyst, McCune-Albright, CAH,
 girls 6–8 or boys 8–9: 2026 guideline]              adrenal/testicular tumour]
             |                                                     |
[GnRH agonist when treatment indicated]         [Treat the specific cause]

Precocious Puberty

Defined as the appearance of secondary sexual characteristics before 8 years in girls (breast development) or 9 years in boys (testicular volume $\ge 4\text{ mL}$).

1. Central Precocious Puberty (CPP / Gonadotropin-Dependent):
   • True premature activation of the hypothalamic GnRH pulse generator.
   • Biochemical Hallmark: When investigation is indicated, begin with ultrasensitive basal LH. A pubertal value supports CPP; if LH is low despite convincing progression, use GnRH/GnRHa stimulation testing (a peak above about 5 IU/L supports CPP, depending on assay/protocol). Bone age is often advanced.
   • Etiology:
     • Girls: Over 90% are idiopathic.
     • Boys: Intracranial causes are especially important with younger onset or neurological findings. Causes include hypothalamic hamartomas (non-neoplastic heterotopias presenting with precocious puberty and characteristic gelastic [laughing] seizures), optic pathway gliomas (neurofibromatosis type 1), astrocytomas, hydrocephalus, or prior cranial irradiation.
   • Investigation: Obtain brain MRI in younger children (girls under 6, boys under 8) and at any age with CNS findings. The 2026 ESPE/ESE-co-sponsored guideline advises against routine MRI in girls 6–8 or boys 8–9 without CNS findings.
   • Management: Long-acting GnRH analogues (e.g., Leuprorelin, Triptorelin depot) continuously stimulate pituitary GnRH receptors, inducing receptor downregulation, suppressing gonadotropin release, halting pubertal progression, and preserving final adult height.
2. Peripheral Precocious Puberty (PPP / Gonadotropin-Independent):
   • Excess sex steroids derived from the gonads, adrenals, or exogenous exposure, with complete suppression of the HPG axis.
   • Biochemical Hallmark: Suppressed basal LH and FSH with flat, prepubertal response to GnRH stimulation.
   • Etiology:
     • McCune-Albright Syndrome: Triad of polyostotic fibrous dysplasia, large café-au-lait macules with irregular ("coast of Maine") borders, and autonomous recurrent ovarian cysts causing precocious vaginal bleeding. Caused by post-zygotic activating somatic mutations in the GNAS gene ($G_s\alpha$ subunit).
     • Congenital Adrenal Hyperplasia: Excess adrenal androgens cause heterosexual precocity in girls and isosexual pseudoprecocity (pubarche, penile enlargement, but prepubertal testes $<4\text{ mL}$) in boys.
     • Gonadal Tumors: Granulosa cell tumors of the ovary (estrogen-secreting) or Leydig cell tumors of the testis (testosterone-secreting; presents as unilateral, asymmetrical testicular enlargement).
     • Testotoxicosis: Familial male-limited precocious puberty caused by activating mutations in the LH receptor gene.

Delayed Puberty

Evaluate the absence of breast development by 13 years, testicular volume below 4 mL by 14 years, or no menarche by 15 years or within 3 years of thelarche. Arrested pubertal progression also warrants assessment.

1. Constitutional Delay of Growth and Puberty (CDGP):
   • Accounts for >60% to 70% of delayed puberty cases, most common in boys. Normal variant with delayed skeletal maturation and family history of late puberty.
2. Hypergonadotropic Hypogonadism (Primary Gonadal Failure):
   • Characterized by elevated LH and FSH with low sex steroids.
   • Girls: Turner Syndrome (45,X); gonadal dysgenesis (streak ovaries).
   • Boys: Klinefelter Syndrome (47,XXY) (tall stature, small firm testes $<4\text{ mL}$, gynecomastia, elevated gonadotropins in late adolescence); bilateral cryptorchidism; post-chemotherapy/pelvic radiotherapy.
3. Hypogonadotropic Hypogonadism (Central Failure):
   • Characterized by low or inappropriately normal LH and FSH.
   • Kallmann Syndrome: Defective migration of GnRH neurons and olfactory placode; features delayed puberty accompanied by anosmia or hyposmia (KAL1 or FGFR1 mutations).
   • Panhypopituitarism: Craniopharyngioma, midline CNS defects.
   • Functional Hypothalamic Amenorrhea: Chronic illness, anorexia nervosa, malnutrition, intense athletic training.

---

Inborn Errors of Metabolism: Acute Emergency Approach

Inborn errors of metabolism (IEMs) collectively affect 1 in 1,000 live births. In neonates, they present with non-specific, catastrophic deterioration after an initial symptom-free period following the introduction of milk feeds.

Clinical Presentation and Red Flags

• The Clinical Paradigm: A full-term infant born after an uneventful pregnancy and delivery who is initially vigorous and feeds well for 24 to 48 hours, then rapidly develops:
  • Lethargy, somnolence, progressive coma
  • Intractable vomiting, poor feeding, dehydration
  • Tachypnea / hyperventilation (compensatory for metabolic acidosis)
  • Seizures, hypotonia, bicycling movements, or opisthotonos
  • Characteristic Odors:
    • Isovaleric Acidemia: "Sweaty feet" odor
    • Maple Syrup Urine Disease (MSUD): Sweet maple syrup / burnt sugar odor
    • Phenylketonuria (PKU): Mousy / musty odor
    • Glutaric Aciduria Type II: Sweaty feet / acrid odor

The Emergency Diagnostic "Metabolic Quartet"

Collect urgent samples before treatment where feasible, without delaying resuscitation. Four decisive laboratory parameters are:

1. Blood Gas: Identifies metabolic acidosis; calculate the serum anion gap ($[\text{Na}^+] - [\text{Cl}^- + \text{HCO}_3^-] > 16\text{ mmol/L}$).
2. Blood Glucose: Identifies hypoglycemia (hypoketotic vs ketotic).
3. Serum Lactate: Identifies mitochondrial or pyruvate disorders, or secondary lactic acidosis in organic acidemias.
4. Plasma Ammonia: Identifies urea cycle disorders or organic acidemias. Normal neonatal ammonia is $< 100\text{ mcmol/L}$; values $> 150\text{--}200\text{ mcmol/L}$ are critically abnormal.

Critical immediate second-line samples (collect promptly; do not delay urgent treatment): Urine ketones, quantitative plasma amino acids, urine organic acids (GC-MS), and acylcarnitine profile on dried bloodspot.

Algorithmic Differential Diagnosis Based on the Metabolic Quartet

                       [Acute neonatal metabolic collapse]
            [Check blood gas, glucose/ketones, lactate and ammonia]
                                       |
        +------------------------------+------------------------------+
        |                              |                              |
[Marked hyperammonaemia]    [High-gap metabolic acidosis]   [Hypoketotic hypoglycaemia]
[No primary acidosis /     [Ketosis; ammonia may rise]      [Ketones inappropriately low]
 respiratory alkalosis]                |                              |
        |                    [Consider ORGANIC ACIDAEMIA]   [Consider FATTY ACID
[Consider UREA CYCLE        - MMA, propionic, isovaleric      OXIDATION DEFECT]
 DISORDER]                  - Urine organic acids          - MCADD, VLCADD
- OTC: high urine orotate                                   - Acylcarnitine profile
- CPS1, ASS, ASL defects                                    - MCADD: elevated C8
        |                              |                              |
        +-------------------- [Urgent metabolic advice] --------------+
                    [Patterns guide tests; confirm the diagnosis]

Acute Emergency Resuscitation Protocol for Suspected IEM

Contact the metabolic centre urgently. The following anti-catabolic measures principally address intoxication-type crises; treatment must follow the biochemical findings and suspected diagnosis.

1. Halt Toxic Substrate Intake:
   • In hyperammonaemia or suspected organic acidaemia, temporarily stop protein-containing feeds. Reintroduce protein within 24–48 hours with the metabolic team; prolonged withdrawal promotes catabolism.
2. Reverse Catabolism and Promote Anabolism:
   • Start high-rate intravenous 10% Dextrose with electrolytes to achieve a Glucose Infusion Rate (GIR) of 8 to 10 mg/kg/min: $\text{GIR (mg/kg/min)} = \frac{\text{Glucose Concentration (\%)} \times \text{Infusion Rate (mL/h)}}{6 \times \text{Body Weight (kg)}}$
   • High GIR suppresses endogenous proteolysis and lipolysis. If hyperglycemia ($>10\text{--}12\text{ mmol/L}$) develops, do not decrease dextrose delivery; instead, initiate a low-dose intravenous insulin infusion ($0.02\text{--}0.05\text{ U/kg/h}$) to facilitate cellular glucose uptake and maximize anabolism.
3. Ammonia Detoxification (Scavenger Therapy):
   • For acute hyperammonemia, administer intravenous Sodium Benzoate and Sodium Phenylbutyrate:
     • Sodium benzoate conjugates with glycine to form hippurate, excreted by the kidneys.
     • Sodium phenylbutyrate / phenylacetate conjugates with glutamine to form phenylacetylglutamine, excreted in urine.
     • Both pathways bypass the defective urea cycle, excreting nitrogen waste.
   • Administer intravenous L-Arginine Hydrochloride (replenishes urea cycle intermediates in ASS/ASL deficiencies).
4. Cofactor Therapy:
   • Administer high-dose Hydroxocobalamin (Vitamin $B_{12}$) for suspected methylmalonic acidemia.
   • Administer Biotin for multiple carboxylase deficiency.
   • Administer L-Carnitine (50–100 mg/kg/day) to conjugate and eliminate toxic organic acyl groups (hold during acute phase of suspected long-chain FAODs due to arrhythmogenic acylcarnitine intermediates).
5. Extracorporeal Dialysis (CVVHD / Hemodialysis):
   • Mandatory first-line intervention if plasma ammonia is $> 400\text{ to }500\text{ mcmol/L}$, or if ammonia rises rapidly despite scavenger therapy, or in intractable life-threatening metabolic acidosis. Peritoneal dialysis is vastly inferior and inadequate for hyperammonemic coma.

---

Childhood Obesity

• Definition: for ages 5–19 years, WHO BMI-for-age above +1 SD indicates overweight and above +2 SD indicates obesity; national programmes may use their own BMI centile charts.
• Causes: most obesity is multifactorial (energy-dense diet, low activity, short sleep, screen time, family and socioeconomic factors). Suspect an endocrine cause when weight gain is accompanied by short stature or slowing height velocity (hypothyroidism, Cushing syndrome, growth hormone deficiency), whereas simple obesity usually accompanies normal or tall stature. Suspect a genetic cause with severe obesity before 5 years with hyperphagia (for example MC4R or leptin-pathway defects), developmental delay or dysmorphism, or Prader–Willi syndrome. Hypothalamic injury and drugs such as glucocorticoids and antipsychotics also cause weight gain.
• Complications: hypertension, dyslipidaemia, insulin resistance with acanthosis nigricans, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnoea, idiopathic intracranial hypertension, slipped capital femoral epiphysis, Blount disease, polycystic ovary syndrome and psychosocial harm including bullying and depression.
• Assessment: plot BMI, measure blood pressure with an appropriately sized cuff, examine for acanthosis nigricans, and screen for comorbidities such as glucose or HbA1c, lipids and liver enzymes according to local guidance.
• Management: a non-stigmatising, family-based, multicomponent behavioural programme addressing diet, physical activity, sleep and screen time. For adolescents aged 12 years or older with obesity, EMA-authorised GLP-1 receptor agonists such as liraglutide or semaglutide may be added to diet and activity. Bariatric surgery is reserved for severe adolescent obesity in specialist centres.

Sources: WHO BMI-for-age (5–19 years); EMA Wegovy product information; Endocrine Society paediatric obesity guideline.